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Pancreatic ductal adenocarcinoma (PDAC)  is a lethal disease, mainly due to late 
diagnosis and its intrinsic resistance to available treatments. Similarly to many solid 
cancers, PDAC contains a rare population of highly tumorigenic „stem-like‟ cells (CSC, 
cancer-stem cells), which have been shown to possess distinct features as compared to 
more differentiated cells composing the bulk of a tumour. While more differentiated 
cells are thought to succumb to the effects of chemotherapy, CSCs survive drug 
treatments and cause relapses by rapidly repopulating tumours. However, CSCs 
represent only a small fraction (1-5%) of neoplastic cells in tumour, which makes their 
study challenging. Previous studies have shown that pancreatic CSCs can be enriched in 
vitro as anchorage-independent spherical colonies expressing stem cell markers (e.g., 
CD133 and autofluorescence). In vitro three-dimensional (3D) cultures, including 
organoids, are emerging as novel systems to study tissue development and 
organogenesis. Here, we report the characterization of CSCs in pancreatic tumour 
cultures established from patient derived xenograft (PDX) of PDAC. We established 
organoid cultures from four PDX-tumours and showed that they are epithelial cultures 
enriched for cells expressing stem cell markers (e.g., autofluorescence) and displaying 
high expression of pluripotency-associated genes as compared to their corresponding 
more differentiated monolayer cell cultures. Most importantly, following transplantation 
in immunodeficient mice, organoids were capable of recapitulating the morphological 
heterogeneity of the parental tumour. Our results highlight the enhanced stemness 
potential of PDAC organoids and their potential value as an in vitro model system to 
study CSCs. 3D systems have recently emerged as advanced drug screening platforms 
as, unlike the 2D cell cultures, organoids more adequately mimic the cell and tissue 
architecture observed in vivo. Our preliminary data show that PDAC organoids are more 
resistant than conventional monolayer cell cultures to standard chemotherapy with 
gemcitabine and abraxane aligning them with the resistance/sensitivity profile usually 
observed in vivo. Thus, pancreatic organoids can be used to model PDAC and as drug 
screening platforms to predict clinical responses and personalised cancer treatments. 
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ABCG2 ATP-binding cassette sub-family G member 2 
ABC Transporter ATP-binding cassette Transporter 
ABX Abraxane 
APC Adenomatous Polyposis Coli 
ALDH-1 Aldehyde dehydrogenases family 1 
BMP Bone morphogenic protein 
BSA Bovine Serum Albumine 
bFGF Basic fibroblast growth factor 
CFTR Cystic fibrosis transmembrane conductance regulator 
CSC Cancer Stem Cell 
CSCs Cancer Stem Cells 
CXCR4 Chemokine receptor type 4 
DAPI 4‟,6- diamidino-2-phenylindole 
DMEM/ F12 Dulbecco‟s Modified Eagle-Medium: Nutrient Mixture F-12 
DNA Deoxyribonucleic acid 
ECM Extracellular matrice 
EGF epithelial growth factor 
EGFR Epithelial growth factor receptor 
EpCAM Epithelial cell adhesion marker 
ESC Embryonic stem cell 
FACS Fluorescent-activated cell sorting 
FBS Fetal bovin serum 
FFPE Formalin-Fixed, Paraffin-Embedded 
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FGF Fibroblast growth factor 
LRP Lipoprotein receptor related protein 
GEM Gemcitabine 
GEMMS Genetically enginnered mouse models 
LGR5 Leucine-rich repeat-containing G-protein-coupled receptor 5 
mRNA Messenger ribonucleic acid 
OCT 3/4 Octamer-binding transcription factor 4 
PanIN Pancreatic intraepithelial neoplasia 
PDAC Pancreatic ductal adenocarcinoma 
PBS Phosphate buffered saline 
PDX Patient derived xenograft 
RT-qPCR quantitive real time polymerase chain reaction 
RNA Ribonucleic Acid 
RPMI Roswell Park Memorial Institute medium 
SMAD4 SMAD family member 4 
SOX2 SRY (sex determining region Y)-box 2 
STREP Streptomicyn 
TCIs Tumour-initiating cells 
2D Two-dimensional 
3D Three-dimensional 
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1 Pancreatic cancer  
According to the National Institute of Cancer, pancreatic cancer is a malignant growth 
of the different cell types that form the pancreas 
(https://www.cancer.gov/types/pancreatic). Pancreatic cancers can be divided into 
exocrine and endocrine tumours, depending on the cell origin of the tumour. Exocrine 
pancreatic tumors are further divided into adenocarcinomas and a variety of other 
pancreatic neoplasms (Bosman et al. 2010). This work is focused on pancreatic ductal 
adenocarcinoma, the most frequent and lethal type of pancreatic cancer.  
 
 
 
1.1 Pancreatic Adenocarcinoma 
 
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma 
(PDAC), which accounts for approximately 90% of all pancreatic cancer cases (Morris 
et al., 2010). PDACs usually arise from precursor lesions in the pancreatic ducts, which 
present with mucinous production and generally form cysts (mucinous cystic neoplasms 
and intraductal papillary mucinous neoplasms) (Figure 1). Mucinous cystic neoplasms 
form in the pancreatic tail and rarely become invasive, whereas intraductal papillary 
mucinous neoplasms are localized in the pancreatic head and can progress to invasive 
adenocarcinoma and metastasize (Morris et al., 2010). The lesions that most frequently 
lead to PDAC are the pancreatic intraepithelial neoplasias (PanINs). PanINs are flat 
epithelial lesions confined to pancreatic ducts (Figure 2). They have been extensively 
characterized, and the histological changes observed in the small pancreatic ducts 
correlate with genetic alterations primarily involving activation of the KRAS oncogenic 
pathway. KRAS activation is followed by a sequence of mutations that will eventually 
lead to invasive PDAC, including inactivation of several key tumor suppressors such as 
CDKN2A and P53 (Bardeesy and DePinho, 2002; Morris et al., 2010). Non-ductal 
neoplasms account for approximately 10% of pancreatic cancer cases and are divided in 
pancreaticoblastoma, acinar cell carcinoma and solid-pseudo papillary neoplasms. 
12 
 
These tumours are both histologically and genetically distinct from adenocarcinomas 
since they develop following mutations in the β-catenin pathway, highlighting the 
importance of particular molecular pathways to different types of pancreatic tumours 
(Table 1). Patients suffering from non-ductal neoplasms have better prognosis, with 
significantly longer survival than patients with adenocarcinomas (Morris et al., 2010). 
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Table 1. Types of exocrine tumours of pancreas.  
 
Types 
Cell of 
origin 
Mean 
survival 
Description 
Histological 
features 
Genes involved 
Acinar Cell 
Carcinoma(ACC) 
Acinar cells 18 months 
Very rare; 
production of 
lipase 
Cell clusters 
close to the 
lumen 
APC, β- 
Catenin, CTNNB1, 
KRAS, P53,BRAF, 
BRCA2 
Pancreatico blastoma Acinar cells 
Over 4 
years 
Primarily in 
children 
under the age 
of 10 
Clusters of 
squamoid 
cells 
APC,    β- 
Catenin, CTNNB1 
Solid Pseudo-papillary 
Neoplasm 
Primordial 
cells 
Over 3 
years 
Found in 
women in 
their 
30‟s,curable 
with surgery 
Dyscohesive 
cell sheets, 
often 
necrosis 
APC, β- 
Catenin, P53, 
SMAD4 
Intraductal Papillary-
Mucinous Neoplasm 
(IPMN) 
Mucin-
producing 
cells 
Curable if 
detected 
early 
Papillary, 
projection 
into the duct. 
Precursor for 
PDAC 
Dysplasia; 
villi growing 
from large 
ducts 
KRAS, P53, 
PIK3CA, 
STK11/LKB1 
Mucinous Cystadeno 
carcinoma (MCN) 
Mucin-
producing 
cells; no 
ductal 
involvement 
Long term 
Rare 
malignant, 
precursor for 
PDAC 
Cystic 
tumor, filled 
with mucin 
KRAS, GNAS, 
RNF43 
Pancreatic Intra 
epithelial neoplasias 
(PanIN) 
Epithelial 
cells 
Curable if 
detected 
early 
Progressive 
lesions; 
precursor for 
PDAC 
Mucin 
production, 
small ducts 
KRAS, 
CDKN2A, 
P53, 
SMAD4, BRCA2 
Ductal Adeno 
carcinoma (PDAC) 
Mainly 
ductal cells, 
but acinar 
and islet cells 
can lead to it 
6 months 
90% of 
pancreatic 
cancer 
Poorly to 
moderately 
differentiate d 
gland structures 
KRAS, 
CDKN2A, 
P53, 
SMAD4, ATM, 
BRCA2, PALB2, 
CTNNB1 
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Figure 1. Anatomy of human pancreas (Image from OpenStax, Exocrine and Endocrine Pancreas, 2013, 
http://cnx.org/content/col11496/1.6/. Licenced under CC BY 3.0 
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Figure 2. Progression model for pancreatic cancer (Adapted from Klein et al., 2002).   
 
 
 
1.2 Epidemiology 
 
Pancreatic ductal adenocarcinoma is only the tenth most frequent form of cancer in the 
United States, but it is currently the fourth leading cause of cancer deaths. There was an 
estimated 53,070 new PDAC cases for 2016, with high predicted rates of mortality 
(41,780 estimated deaths for 2016) (American Cancer Society).  
PDAC is so lethal because it is virtually asymptomatic in its early stages; consequently 
it escapes diagnosis until the cancer is locally advanced or metastatic (Hustinx et al., 
2005). As such, prognosis and survival are poor for patients suffering from this disease, 
with a 5-year survival at just 6%. The only established “curative” option for PDAC 
patients is resective surgery to remove the primary tumour. Unfortunately, most patients 
(80%) are too far advanced to justify this surgery and are placed on largely ineffective 
chemotherapy regimens. When surgery is performed, it is used in conjunction with 
irradiation and/or chemotherapy, and the 5-year survival for patients is increased up to 
25 to 35% (Oettle et al., 2007). While surgery yields a significant improvement in 
outcome, most patients still succumb quickly to the disease because PDAC tumours are 
often minimally responsive or resistant to chemotherapeutic treatments (Hidalgo, 2010). 
16 
 
1.3 Treatment Options 
 
The standard of care in PDAC therapy for all patients, regardless of whether or not 
surgery was performed, is a regim that includes the nucleoside analogs gemcitabine 
(GEM) and/or 5-fluorouracil (5-FU). These drugs have been the best options for PDAC 
patients even though their effectiveness is limited and they are estimated to extend 
lifespan by only a matter of weeks (Burris, 2005). Several single agent and GEM-based 
combination therapies have been tested (Table 2), with minimal improvement in the 
outcome (Hidalgo, 2010; Ying et al., 2012). Sadly, the median survival for PDAC 
patients remains short at approximately 6 months (Hidalgo, 2010; Siegel et al., 2012). In 
2011, a study published in the New England Journal of Medicine reported that a 
combination of 5-FU, leucovorin (also called folinic acid), irinotecan and oxaliplatin 
(FOLFIRINOX) increased survival of metastatic PDAC patients to 11.1 months, nearly 
doubling survival (median of 6.8 months) for patients on GEM therapy alone (Conroy et 
al., 2011).  
 
 
Table 2. Available therapeutic options for the treatment of PDAC (Adapted from Han and Von Hoff, 
2013). 
CLINICAL REGIMENTS PROVEN TO INCREASE SURVIVAL FOR PATIENTS WITH 
ADVANCED METASTATIC PANCREATIC CANCER 
Regimen Control Median Survival (months) 
Regimen           Control 
Reference 
Gemcitabine  5-FU 5.6 4.4 Burris et al.,1997 
Gemcitabine + 
Erlotinib 
GEM 6.24 5.91 Moore et al.,2007 
FOLFIRINOX
** GEM 11.1 6.8 Conroy et al.,2011 
Nab-paclotaxel + 
gemcitabine 
GEM 8.5 6.7 Von Hoff  et al., 
2012 
*
GEM: gemcitabine       
**
FOLFIRINOX: Folinic acid + 5-FU + Irinotecan + Oxaliplatin 
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However, a recent phase III clinical trial combining gemcitabine with abraxane (a 
protein-bound form of paclitaxel) showed prolonged survival compared to gemcitabine 
alone (8.5 vs 6.7)  (Han and Von Hoff, 2013).  
The inability to detect PDAC early in its development and the lack of effective therapies 
highlight an urgent need to identify clinically relevant biomarkers of PDAC that will 
improve its diagnosis and treatment. Therefore, there is a drive to identify genes and 
pathways that predict a patient‟s survival (prognostic markers) and responsiveness to 
chemotherapies (predictive markers). Such knowledge will likely help stratify patients 
for clinical trials testing new therapies or placement on an established treatment regimen 
predicted to be successful for that individual. This reflects a movement by cancer 
researchers and physicians towards personalized therapies in the clinical management of 
all cancers, including PDAC (Hanahan and Weinberg, 2000). This movement is based 
upon the recognition that 1) cancer is a heterogeneous disease, with each tumour 
bearing distinct molecular and genetic signatures, and 2) each patient has a unique 
genome that differentially influences tumour development and response to anticancer 
therapies. 
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2 Cancer stem cells  
 
Cancer stem cells (CSCs), also termed tumor-initiating cells, are defined as a 
subpopulation of cancer cells with self-renewing capacity that possess high tumorigenic 
potential and can undergo multilineage differentiation to give rise to all types of cells 
present within the malignancies (Clarke et al., 2006). According to the CSC model, 
CSCs drive tumour growth and these cells are considered to be the underlying cause of 
tumour relapse and disease progression, also through their resistance to therapy and 
metastatic potential. Therefore, CSCs are currently extensively studied in various 
cancers. 
Although the CSC hypothesis is very old (Virchow, 1855), the field of CSC research 
truly started about 20 years ago when Dick and colleagues published their pioneer 
studies demonstrating that only minor subpopulation of acute myeloid leukemia cells 
with CD34+/CD38− phenotype holds the potential to initiate leukemia in 
immunodeficient mice (Lapidot et al., 1994; Bonnet and Dick, 1997). Since then, a 
large body of evidence has been published that supports the essential role of CSCs in 
initiation and progression of several hematological malignancies and of a wide range of 
solid tumours (Beck and Blanpain, 2013). 
 
 
 
2.1 Cancer stem cell model 
 
Cellular heterogeneity is a common feature of a spectrum of human malignancies 
ranging from solid tumours to hematological malignancies and this intratumoral 
heterogeneity represents one of the greatest challenges in cancer therapeutics (Kleppe 
and Levine, 2014; O‟Connor et al., 2014; Zellmer and Zhang, 2014; Brooks et al., 
2015).  
In general, two models are proposed to explain tumour growth and heterogeneity 
(Figure 3). According to the stochastic model (Figure 3a), all tumour cells are 
equivalent and proliferate to fuel tumour growth (Beck and Blanpain, 2013). 
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Conversely, the CSC model proposes that only certain cells contribute to long-term 
tumour growth (Figure 3b) and these CSCs generate, analogously to normal stem cells, 
more restricted progenitor cells with limited replicative/self-renewal capacity. However, 
it is believed that these progenitors may transiently extensively proliferate and thus 
constitute the bulk tumour (Kreso and Dick, 2014). 
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Figure 3.  Tumour growth models. (a) In the stochastic model of tumour growth, all tumour cells are 
equipotent and stochastically self-renew or differentiate, leading to intratumoural heterogeneity. (b) In the 
CSC model, only a subset of cells with the capacity of long-term self-renewal is responsible for sustained 
tumour growth. These CSCs give rise to more committed progenitors with limited proliferative potential 
that eventually terminally differentiate. (c, d) Clonal evolution resulting from new somatic mutations may 
further increase intratumoural cellular heterogeneity in both stochastic and CSC model. As suggested 
Driessens et al. (2012) clonal evolution in the CSC model may also originate from intrinsic nature of 
CSCs themselves, as every CSC within a tumour is equally likely to clonally expand due to neutral 
completion between these cells (Illustrations created based on Beck and Blanpain, 2013). 
 
 
 
It is widely accepted, that tumour cell subpopulations evolve through accumulation of 
genetic and epigenetic mutations, some of which may increase the fitness and survival 
of the individual clone, and thus promote its expansion in the respective tumour 
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microenvironment (Greaves and Maley, 2012). Importantly, clonal evolution may occur 
in both stochastic model (Figure 3c) and CSC model (Figure 3d) of tumourigenesis. 
Several studies have shown that differentiated or neoplastic non-stem cells are able to 
re-enter CSC state under certain circumstances. Such cell plasticity has been shown for 
breast carcinoma (Chaffer et al., 2011; Iliopoulos et al., 2011; Chaffer et al., 2013), 
colorectal carcinoma (Vermeulen et al., 2010; Schwitalla et al., 2013), and gliomas 
(Charles et al., 2010). These findings led to the proposal of a fluid CSC model where 
the cell hierarchy is more transient than previously suggested (Figure 4, (O‟Connor et 
al., 2014)).  
 
 
 
 
 
Figure 4. Fluid CSC model. In this extended CSC model of tumour growth, both progenitor cells and 
differentiated cells are able to re-acquire self-renewal potential (indicated by red arrows), thus becoming 
CSCs. That means that although the cells are hierarchically organized with the respect to their stem-like 
characteristics in a certain time point, this hierarchy is more transient and may change during tumour 
progression (Illustration created based on O’Connor et al., 2014 and Beck and Blanpain, 2013). 
 
 
 
However, recent lineage-tracing studies (Rycaj and Tang, 2015) provided clear evidence 
of CSCs across three different types of solid tumors: papilloma and squamous cell 
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carcinoma (Driessens et al., 2012), glioblastoma (Chen et al., 2012), and intestinal 
adenoma (Schepers et al., 2012). In a study by Clevers and colleagues (Schepers et al., 
2012), Lgr5+ intestinal stem cells were individually traced in a transgenic model of 
intestinal adenoma in vivo. This study demonstrated that a single Lgr5+ stem cell was 
responsible for the initiation and maintenance of the tumuor suggesting the presence of 
stem cell activity within primary intestinal adenomas, as precursor to intestinal cancer. 
 
 
 
2.2 Cancer stem cell markers 
 
Identification and/or isolation of cells with CSC phenotype represent the essential step 
to study CSCs. For this purposes, various molecules have been evaluated for their 
ability to selectively mark CSC population. In the initial studies, different cell surface 
proteins were used to distinguish CSCs from other cancer cells. In mid-1990‟s, the 
research group of John Dick sorted acute myeloid leukemia cells for CD34+/CD38− 
phenotype and showed that this cell fraction exhibited significantly higher capacity to 
initiate leukemia after injection into immunodeficient mice (Bonnet and Dick, 1997; 
Lapidot et al., 1994). Since then, a wide range of cell surface proteins has been 
proposed as CSC markers in many types of tumours.  
The first evidence for the existence of CSCs in pancreatic cancer was provided by Li et 
al. (2007), through the identification of a highly tumourigenic CD44+CD24+EpCAM+ 
subpopulation using a xenograft model of immunocompromised mice for primary 
human pancreatic adenocarcinoma. This subpopulation was able to generate tumors 
from as few as 10
2 
cells in 50% of the animals, showing a high tumourigenic capacity. 
By the contrast, CD44-CD24-EpCAM-, the negative population for these markers, was 
not capable to generate tumours until 10
4 
or more cells were implanted. 
CD44+CD24+EpCAM+ cells displayed typical stem cell phenotypes, such as self-
renewal capacity, generation of progenies and recapitulation of the morphological 
heterogeneity of the parental tumour from which they were derived.  
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Using a different cell surface marker, Hermann et al. (2007) showed that the expression 
of CD133 in freshly isolated primary human pancreatic tumours identified a population 
with self-renewal capacities, and most importantly, exclusive in vivo tumourigenicity. 
Importantly, CD133+ cells maintained their tumour-initiating capability during serial 
passaging in vivo. Interestingly, they also showed that the CD44+CD24+EpCAM+ 
subpopulation partially overlapped with the CD133+ population. Distinct subpopulation 
of CD133+ cells that co-expressed CXCR4 was further identified in the invasive front 
of the PDAC tumors. These CD133+CXCR4+ cells were shown to have migratory 
capacity in vitro and were demonstrated to be essential for the metastatic phenotype of 
the PDAC in vivo. Although CD133+CXCR4− formed tumours at the same rate, only 
mice injected with CD133+CXCR4+ cells developed metastases. In accordance with 
these results, another study showed that CXCR4 is expressed in pancreatic 
intraepithelial neoplasias (PanIN) and its expression increases during PanIN progression 
towards invasive carcinoma (Thomas et al., 2008). The possible prognostic significance 
of CXCR4 in PDAC was further confirmed by a meta-analysis study showing 
correlation between CXCR4 expression and poor prognosis (Krieg et al., 2015). More 
importantly, strong association of CXCR4 expression and metastatic disease was 
identified in this study. Consistent with these findings, previous experimental data 
demonstrated increased proliferation and invasiveness of pancreatic cancer cells after 
induction of CXCR4 by its ligand CXCL12 (Shen et al., 2013). Although CD133 was 
initially suggested as a CSC marker in PDAC (Hermann et al., 2007), subsequent 
studies argued against the usefulness of this protein alone to specifically identify 
pancreatic CSCs. Immervoll et al. (2008) showed that CD133 is expressed not only in 
pancreatic cancer cells but also in normal pancreas. Moreover, no correlation of CD133 
and patient survival was found in several studies (Immervoll et al., 2008; Kure et al., 
2012). Co-expression of CD44 and CD133 was then proposed as more specific 
phenotype of CSCs (Immervoll et al., 2011), and was shown to predict worse survival in 
PDAC patients (Hou et al., 2014; Chen et al., 2012). However, significance of CD133 
expression in PDAC tumorigenesis has been recently supported by two independent 
studies reporting CD133 as efficient negative prognostic factor (Kim et al., 2012; Li et 
al., 2015). 
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Additional markers have also been used for the characterization of CSCs: ALDH-1 
(Aldheyde Dehydrogebnase-1) (Feldmann et al., 2007; Jimeno et al., 2009; Rasheed et 
al., 2010) has been associated with a high tumourigenic population in pancreatic cancer, 
although more recent data suggest an abundant expression of ALDH-1 in normal 
pancreas tissue as well (Deng et al., 2010),which may compromise the specificity of 
ALDH-1 as a marker for pancreatic CSCs. Indeed, ALDH-1 can be used for tumours 
whose normal tissue expression of ALDH-1 is limited or restricted, such as breast, lung, 
ovarian or colorectal tumors, or for circulating CSCs (Table 3). 
 
 
Table 3. Cancer stem cell markers for pancreatic cancer (Adapted from Dorado et al., 2011). 
 
 
 
Pancreatic CSCs are subject to regulation by some of key embryonic stem cell (ESC) 
transctiption factors. ESC transcription factors are important DNA-binding proteins 
present in both embryonic and adult somatic cells. The critical role of these factors in 
reprogramming processes makes them essential not only for embryonic development 
but also tumorigenesis. Recently, it has been shown that these ESC markers SOX2, 
OCT4, and NANOG are expressed in PDAC and that these transcription factors may 
associate with drug resistance, metastasis and overall worse prognosis (Herreros-
Villanueva et al., 2014). Regarding pancreatic CSCs, particularly SOX2 expression 
Pancreatic Ductal Adenocarcinoma Markers Reference 
Tumour-initiang population EpCAM
+
 CD44
+
 CD24
+
 (Li et al., 2007) 
 
CD133 (Hermann et al.,2007) 
ALDH-1 
(Feldmann et al.,2007, Jimeno 
et al.,2009, Rasheed et al.,2010) 
Side Population/ABCG2 (Kabashima et al., 2009) 
Migrating cancer stem cells CD133+CXCR4+ (Hermann et al., 2007) 
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seems to be crucial for stem-like features of PDAC cells (Herreros-Villanueva et al., 
2013; Singh et al., 2015). Overexpression of SOX2 in vitro induced cell 
dedifferentiation and promoted EMT reprogramming, which is necessary for PDAC 
progression. Moreover, CD44+/EpCAM+ cell fractions isolated from two different 
tumour samples were enriched for SOX2-positive cells (Herreros-Villanueva et al., 
2013). Thus, SOX2 may serve as potential CSC marker in PDAC. 
While numerous cell surface proteins have been positively evaluated in certain settings, 
the expression levels of many of these markers can drastically change based on 
environmental conditions (e.g. tumour digestion, cultivation in different conditions, 
xenografting), and their expression is neither exclusively nor reproducibly linked to a 
functional cancer stem cell phenotype (Hermann et al., 2010).  
Recently an intrinsic autofluorescent phenotype has been identified in CSCs and was 
subsequently established as a novel and functionally relevant tool to isolate and 
characterize pancreatic CSCs down to single cell level (Miranda-Lorenzo et al., 2014). 
Has been shown that this subpopulation of autofluorescent cells could be excited and 
emitted at 490 and 532 nm, respectively (Figure 5).  
  
 
 
 
Figure 5. Spectrum of autofluorescence in primary pancreatic cancer cells (Adapted on Miranda-Lorenzo 
et al., 2014). 
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Specifically, these autofluorescent cells were markedly enriched during chemotherapy, 
strongly expressed pluripotency-associated genes, and were highly invasive both in 
vitro and in vivo. 
This distinct inherent cancer stem cell property represents a novel biological feature that 
is traceable in real time and provides unprecedented robustness and power for the 
identification and purification of CSCs without the use of antibodies nor any kind of 
manipulation, thus drastically reducing experimental errors and artefacts. While surface 
marker panels are regularly tested for only certain cancer types, autofluorescence has 
already been shown to identify CSCs across many tumor types including pancreatic, 
breast, lung, liver and colorectal cancer (Miranda-Lorenzo et al., 2014). 
 
 
 
2.3 Spheroid models for study cancer stem cells 
 
Spheroid cancer models represent a major 3D in vitro model that  has been described, 
over the past 4 decades, regarding cancer stem cell research. The terms “tumour 
spheroid” or “tumourspheres” (Gupta et al., 2009; Lin et al., 2011) were used to 
describe CSC spheres issued from different types of cancer having a large panel of 
derived names. Cultivation of CSC as a free-floating sphere (tumoursphere) was first 
described in brain tumours by Singh et al. (2003). Initially, the quantification and 
characterization of such floating spherical aggregates had been developed for normal 
neural stem cells grown as neurospheres, in which a single cell is able to give rise to a 
sphere by clonal expansion (Reynolds and Weiss, 1992; Uchida et al., 2000). In the 
following years, spheres were developed from a wide range of solid tumours, including 
breast (Ponti et al., 2005), lung (Eramo et al., 2008), colon (Ricci-Vitiani et al., 2007), 
prostate (Collins et al., 2005), pancreas (Li et al., 2007), and ovarian (Zhang et al., 
2008) cancers, under that same assumption that “sphere assays” enable measuring self-
renewal capacity. In addition to the identification of cancer stem-like properties, spheres 
derived from PDAC were proved to be resistant to chemotherapy and tumourigenic 
agents (Lonardo et al., 2015). Tumourspheres have been proven to be an excellent 
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model for enriching the CSC fraction but not for studying intrinsic properties of CSCs 
related to their 3D architecture. Furthermore, this system does not fully reproduce the 
tumour from which the cells are derived, especially its structure and/or 
microenvironment (Kim et al., 2012).  
 
 
 
2.4 Implication for clinical practice 
 
As proposed by CSC model, intratumoural heterogeneity is generated by CSCs which 
give rise to the different populations of cells. More differentiated cells, may extensively 
proliferate for a certain time period, and are thought to represent the tumour bulk; 
however, this may not be true in all cases, as suggested by Driessens et al. (2012). 
Driessens and colleagues, using clonal analysis in invasive squamous cell carcinoma, 
showed a different pattern of behaviour, consistent with geometric expansion of a single 
CSC population with limited potential for terminal differentiation. This study presents 
the first experimental evidence for the existence of CSCs during unperturbed solid 
tumour growth (Driessens et al., 2012).  
Current conventional anti-cancer therapies target the tumour bulk, but have limited or 
no effect on the CSCs. If CSCs are the primary drivers of tumourigenesis and 
metastasis, then effective anti-cancer therapies must target these cells (Figure 6). 
In clinical practice, patients often relapse and their prognosis is poor despite the initial 
remission of the tumour. CSCs are considered to be the cause of the observed tumour 
recurrence because of their resistance to therapy and their increased metastatic potential 
(Shamir and Ewald, 2014; Cojoc et al., 2015). Several mechanisms of this resistance 
were suggested: (i) efflux of chemotherapeutic mediated by upregulation of ABC 
transporters; (ii) high ALDH activity that allow CSCs to quickly metabolize different 
chemotherapeutics; (iii) enhanced response to DNA damage and prevention of this 
damage by efficient scavenging of reactive oxygen species; (iv) autophagy that enables 
CSCs to overcome microenvironmental insults like hypoxia, starvation or treatment; (v) 
microenvironmental stimuli provided by the specific CSC niche (Cojoc et al., 2015). 
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Targeting CSCs itself or exploiting these mechanisms of CSC resistance might improve 
cancer treatments (Chen et al., 2012). Nevertheless, to achieve these improvements, a 
key step is to identify and characterize the targets of such treatments – CSCs – in the 
respective tumour types.  
 
 
 
 
 
 
 
 
Figure 6. Implications of CSCs in cancer treatment. Conventional anti-cancer therapies that kill primarily 
non-tumourigenic cells (blue, gray) can shrink the tumour, but will not eradicate the tumour because these 
therapies do not target CSCs, which will eventually regenerate the tumour or initiate metastases. CSC-
targeted therapies represent potential treatment improvements because they will kill or differentiate CSCs, 
thus targeting tumourigenesis, tumour growth and tumor metastasizing. However, it is evident that 
treatment combining both CSC-targeted and conventional therapy will be necessary to completely 
eradicate the tumour (Illustration created based on Pardal et al., 2003). 
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 3 Three-dimensional organoid cultures 
 
 
3.1 A brief introduction on organoids 
 
In vitro three-dimensional (3D) cultures are emerging as novel systems to study human 
tissue development and disease. The 3D culturing of normal cells was introduced in the 
early 1970s when James Rheinwald and Howard Green described the first long-term 
culture: the formation of Keratinizing colonies from single cells. They combined freshly 
isolated keratinocytes with irradiated mouse 3T3 fibroblasts. As in stratified skin, cell 
division was confined to the basal layer of the growing clones, while surficial layers 
consisted to terminally differentiating keratinocytes that gradually developed a cornified 
cell envelope. While the term “organoid” was not used in these pioneering studies, 
Rheinwald and Green were the first to reconstitute 3D tissue structure from cultured 
human stem cells.  
The term “organoid” has historically been used loosely to encompass the 3D 
organotypic cultures derived from primary tissue, established cell lines, as well as 
whole or segmented organs such as organ explants consisting of multiple tissue types 
(Shamir and Ewald, 2014). An organoid is defined as a 3D structure grown from stem 
cells and consisting of organ-specific cell types that self-organizes through cell sorting 
and spatially restricted lineage commitment (Clevers, 2016). 
In semisolid matrices, epithelial cells can develop polarized structures as a result of the 
assembly of cell-cell contacts and cell/matrix interactions that simulate the basement 
membrane. Most of the documented organoid cultures contain functional tissue units 
that lack the mesenchymal, stromal, immune and neural cells that intersperse the tissue 
in vivo. These organoids rely on artificial extracellular matrices (ECM) to facilitate their 
self-organization into structures that resemble native tissue architecture.  
Unlike more traditional in vitro cultures, organoids are similar to primary tissue in both 
their composition and architecture, harbouring small population of genomically stable 
cells, can be expanded indefinitely, cryopreserved as biobanks and easily manipulated 
using techniques similar to those established for traditional 2D monolayer culture. 
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Organoids represent an important bridge between traditional 2D cultures and in vivo 
mouse/human models, as they are more physiologically relevant than monolayer culture 
models and are far more amenable to manipulation, signaling pathways and genome 
editing than in vivo models (Huch et al., 2013; Sato et al., 2011; Fatehullah et al., 2016). 
Researchers have long known of the self-organizing capacity of cells and have 
harnessed this ability to generate 3D cultures from primary tissues, but the development 
of the intestinal organoid culture system in 2009 was a major technological advance for 
the stem cell field. Unlike previous systems, this new method made use of our 
knowledge of endogenous intestinal stem cell niche components to deliver a well-
defined, stable culture system capable of sustaining the long-term growth of near-
physiological epithelia from purified Lgr5+ stem cells or isolated crypts. The culture 
system was surprisingly simple, using Matrigel as an ECM substitute, supplemented 
with growth factors constituting key endogenous niche signals: WNT, a Frizzled/LRP 
(lipoprotein receptor related protein) ligand; Noggin, a BMP (bone morphogenetic 
protein) inhibitor, to allow for stem cell expansion; R-spondin, an LGR4/5 (leucine-rich 
repeat-containing G-protein-coupled receptor 4/5) ligand, a WNT agonist to maintain 
stem cell populations; and EGF (epithelial growth factor), an EGFR ligand, to promote 
cell proliferation. Remarkably, these organoids faithfully recapitulated the in vivo tissue 
architecture and contained the full complement of stem, progenitor and differentiated 
cell types. The system was subsequently adapted for generating human intestinal 
organoids, as well as organoids from other organs harbouring Lgr5+ stem cells, 
including the colon, stomach and liver (Sato et al., 2011; Huch et al., 2013). 
 
 
 
3.2 Tumour organoids as potential model for drug screening 
 
As recently demonstrated, intestinal organoids have unique features as they efficiently 
form, self-renew, and expand long-term while remaining genetically stable (Sato et al., 
2011). Using this system, organoids can be indeed readily established from surgically 
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resected intestinal tissue and endoscopic biopsies of patients suffering from adenomas 
and adenocarcinomas (Sato et al., 2011).  
Patient-derived organoids represent an important resource for developing personalized 
treatment. Cancers have many subtypes, which display different combinations of 
genetic alterations. This diversity is important to understand in patients: cancer drugs 
specifically target different cellular pathways, so depending on the genetic background 
of the person and of the tumour, patients‟ response to therapy may vary. Recently, 
Ogawa et al. (2015) were able to correct CFTR (cystic fibrosis transmembrane 
conductance regulator) misfolding and translocation to cell membranes in patient-
derived cholangiocyte organoids, using inhibitors to reduce misfolding and stabilize the 
protein. This demonstrates the utility of the organoids for testing and screening novel 
compounds to treat various conditions. In vitro amplification of patient organoids from 
disease-site biopsies can deliver sufficient material for deep sequencing to reveal causal 
mutations, or for in-depth phenotypic profiling to facilitate more tailored treatment 
regimes. Organoids open up new avenues for regenerative medicine and, in combination 
with editing technology, for gene therapy. The many potential applications of this 
technology are only beginning to be explored. 
 
 
 
3.3 Pancreatic organoids 
 
Establishing 3D organoids from epithelial organs required tissue-specific modifications 
that reflect the individual requirements and lineage commitment factors for the resident 
stem cell populations and their progeny.  
To establish pancreatic cultures, isolated pancreatic duct fragments from adult healthy 
mice (Figure 7A) were embedded in Matrigel containing the „generic‟ organoid culture 
factors EGF, RSPO1 and Noggin (Sato et al., 2009) supplemented with FGF10 
(Bhushan et al., 2001) and Nicotinamide. Under these conditions, small duct fragments 
formed closed structures within 24-48h that expanded into budding cyst-like organoids 
(Figure 7B)(Huch et al., 2013). 
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Figure 7. Establishment of the pancreatic organoids from adult pancreatic ducts. (A) Scheme representing 
the isolation method of the pancreatic ducts and the establishment of the pancreatic organoid culture. The 
pancreatic ducts were isolated from adult mouse pancreas after digestion, handpicked manually and 
embedded in matrigel. Twenty-four hours after, the pancreatic ducts closed and generated cystic 
structures. After several days in culture, the cystic structures started folding and budding. (B) 
Representative serial DIC images of a pancreatic organoid culture growing at the indicated time points. 
Magniﬁcations: x 10 (days 0, 2, 4, 6, and 8) and x 4 (day 10 onwards). (Illustration from Huch et al., 
2013). 
 
 
 
 
Importantly, engraftment of these pancreatic organoids under the kidney capsule 
resulted in the formation of functional pancreatic tissue containing ductal, endocrine and 
acinar cells, providing strong evidence that pancreatic stem cell potential resides in the 
adult ductal compartment (Huch et al., 2013). 
Similar observations were made for human pancreatic organoids (Boj et al., 2015). 
Pancreatic organoids derived from wild-type mice and PDAC genetically enginnered 
mouse models (GEMMs) accurately recapitulate physiologically relevant aspects of 
disease progression in vitro. Following orthotopic transplantation, these organoids were 
capable of regenerating normal ductal architecture, unlike other 3D model systems. 
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It is widely accepted that CSCs are key players in tumor initiation, progression, drug 
resistance and recurrence. Therefore, targeting unique features of CSCs might represent 
an ideal strategy for cancer eradication. Individual surface marker, such as CD133, or 
combination of markers such as EpCAM/CD44/CD24 have been proposed to enrich for 
pancreatic cancer stem cells (CSC) in fresh tumor samples. These cell subpopulations 
have been found to bear exclusive tumorigenicity and resistance to chemotherapy 
(Hermann et al., 2007). CSCs represent only a small fraction (1-5%) of neoplastic cells 
in tumour, which makes their study challenging. Moreover, the scarce representation of 
stem cells in traditional in vitro models of PDAC prompted us to investigate novel 
culture systems as biological platforms to study CSCs. Recently described 3D culture 
methods, such as organoid cultures, have been shown to recapitulate key features of in 
vivo cell-growth, including self-organization and differentiation. Organoid cultures 
represent an innovative system for culturing primary normal and diseased tissue in vitro, 
thereby enabling the study of human pancreas biology, as well as of pancreatic cancer 
development and progression. Thus, this thesis focuses on the identification and 
characterization of CSCs in organoid cultures established from PDAC patient-derived 
xenograft tumors. Based on our preliminary data concerning expression of CSC markers 
in primary PDAC cultures the specific objectives of this thesis were defined as follows:  
 
1. Establishment and functional characterization of organoid cultures from 
different PDAC Patient-derived Xenograft Tumours. 
2. Comparison of stemness content between different 3D in vitro cultures of PDAC 
models, namely PDAC organoids and sphere cultures. 
3. Comparison of genetic Landscape of 3D-models (organoid and sphere cultures) 
and matched primary tumors. 
4. Assessment of PDAC organoid cultures as drug screening platform for the 
prediction of clinical response. 
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MATERIALS AND METHODS 
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1 ANIMAL MODELS  
 
 
1.1 Study Approval 
Mice were housed in the animal facility of Barts Cancer Institute (QMUL) in 
accordance with institutional policies and federal guidelines. All animal experiments 
were conducted in accordance with procedures approved by the ASRU (Animals in 
Science Regulation Unit) at the QMUL. 
 
 
1.2 Xenografts 
PDAC xenografts from patient derived samples were kindly obtained from the ARC-
Net Biobank (University of Verona, Italy), Department of Surgery at the Technische 
Universität München (Munich, Germany) and Manuel Hidalgo‟s group (CNIO, Spain). 
Briefly, primary tumours were cut into small fragments and then implanted 
subcutaneously in immunocompromised mice (NU- Foxn1
nu
; Charles River, 
Wilmington, MA, USA) with two small tumour pieces per mouse. Once tumours 
reached 1cm
3 
, tumours were resected and re-implanted in another set of female nude 
mice, following the protocol described in Rubio-Viqueira et al. (Rubio-Viqueira et al., 
2006), and represented in Figure 8. 
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Figure 8.  Xenograft study workflow. Tumour samples are implanted in F1 generation and then expanded 
in a cohort of nude mice (Adapted from Rubio-Viqueira et al. 2006). 
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2 CELL CULTURE  
 
 
2.1 Primary human pancreatic cancer cells 
Tumour tissue originating from different PDX models was minced mechanically 
(gentleMACS Dissociator; Miltenyi) and enzymatically digested with Dispase II 
(1mg/ml; MerK Millipore) supplemented with Collagenase P (4mg/ml; Sigma) for 60 
min at 37⁰C under constant rotation. Following digestion, the cells were passed through 
a series of strainers (100, 70 and 40) and the resulting single cell suspension was 
centrifuged for 5min at 1500rpm. Red blood cells were lysed by incubation with ACK 
Lysis buffer (Lonza) for 5min at RT. After neutralization of the buffer with equal 
volume of complete medium and centrifugation, cell pellets were resuspended and 
cultured in complete medium: RPMI Medium 1640 (1X) supplemented with 
GLUTAMAX
TM 
(GIBCO, Life Technologies), 10% FBS, and 50 units/mL pen/strep 
(Invitrogen). 
 
 
2.2 Sphere formation assay 
Spheres were generated by culturing ~2x10
4
/ml primary pancreatic cancer cells in 
Ultra-Low attachment flasks (Fisher Scientific) in suspension using serum-free 
DMEM/F12 (GIBCO, Life Technologies) supplemented with B27 (Fisher Scientific), 
20 ng/mL bFGF (PeproTech), and 50 units/mL pen/strep for a total of 7 days, allowing 
spheres to reach a size of >75µm. For serial passaging, 7-day-old spheres were 
harvested using 40µm cell strainers, dissociated into single cells with Tryspin-EDTA 
(Sigma), and then re-grown for 7 additional days. The CASY Cell Counter (Roche 
Applied Sciences) was used to quantify spheres of three different fractions, 40-80µm, 
80-120µm and >120µm in diameter.   
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2.3 Culture and propagation of organoid cultures from pancreatic PDX models 
Pancreatic organoids were generated by embedding dissociated adherent cells in 
Matrigel, and culturing in organoid growth medium (ADMEM/F12 medium [GIBCO, 
Life Tecnologies] supplemented with B27 [50X, Invitrogen], Glutamax [2mM, 
Invitrogen], HEPES [10mM, Invitrogen], penicillin/streptomicin [1X, Invitrogen], 
Nicotinamide [1.25M, Sigma], N-acetyl-L-cysteine [1.25M, Sigma], Y27632 
[1.6mg/ml, Sigma], SB202190 [10µM, Sigma], Human recombinant Noggin [100µg/ml, 
PeproTech], A83-01 [0.5ng/ml, Abcam], R-spondin [500ng/ml, PeproTech], Human 
recombinant EGF [50ng/ml, PeproTech], Gastrin [10nM, Sigma], FGF10 [10ng/ml, 
PeproTech], and FGF2 [5ng/ml, PeproTech]). Plates were pre-coated with matrigel 
prior to seeding the cells. The medium was changed every 3 days. After fifteen days, 
organoids were incubated with Cell recovery solution (Corning) for 1 hour on ice, 
allowing disrupt the matrigel. After incubation, organoids were washed with 1X of PBS 
(Sigma) and centrifuged for 5 min at 2000rpm, 4⁰C. Cell pellets were resuspended in 2 
ml of TrypLE Express (GIBCO, Life Technologies) and incubated for 5-10 min at 37⁰C. 
An equal volume of complete medium were added as neutralizing solution and 
centrifuged at 1500rpm for 5 min at RT. The supernatant was discarded and the pellet 
was resuspended in 1 ml of fresh complete medium. The suspension was filtered 
through a 50 µm mesh to remove any large cell clusters and viable cells were counted 
on a Neubar chamber. The appropriate concentration of cell suspension per well was 
calculated. This volume was taken and spun for 5min at 2.0rpm and followed by 
dilution into the appropriate volume of matrigel. 
 
 
2.4  Organoid formation assay 
In order to assess the organoid formation efficiency of different primary pancreatic 
cancer models, cells were seeded starting from adherent conditions in regular medium 
into 3D organoid culture. In a 24well plate 10.000 cells were seeded per well and were 
allowed to grow for 2 weeks. The medium was changed every 3 days. At endpoint, on 
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day 14, the organoids were recovered and counted on a Neubar chamber to evaluate the 
number of formed organoids per ml. For the second generation, they were reseeded in a 
new 24-well again in 10.000 cells per well in triplicate. 
 
 
2.5  Cell treatments 
In order to evaluate the chemosensitivity profile of the different PDX models, primary 
human pancreatic cancer cells, sphere-derived cells and pancreatic organoids were 
treated with Gemcitabine (100 ng/mL) and Abraxane (1 µM) for 7 days. In adherent 
conditions, 40.000 PDAC cells were seeded in a 24 well cell culture plate in triplicate, 
in 1mL of complete medium. The treatment started after 24 hrs and was maintained for 
7 days. At endpoint, the viability of the cells was evaluated by the Alamar Blue viability 
assay as described in paragraph 2.6. For the treatment of spheres cells were seeded at a 
density of 10.000 cells/well in 24 Ultra-Low attachment plates in suspension in 
complete sphere medium. Treatment started on day 4 and maintained for 7 days. At 
endpoint, spheres were counted using the CASY cell counter as described in paragraph 
2.2. The treatment of primary pancreatic organoids was performed in a 96 well cell 
culture plate in triplicate. In each well, 5000 cells were seeded and were let to grow in 
complete organoid medium for 7 days. The drug treatment started on day 7 and 
continued for 7 additional days. On the last day the viability of the organoids was 
assessed by the Alamar Blue viability assay. 
 
 
2.6  Cell viability assay 
Cell viability activity was measured by Alamar Blue Assay according to the following 
protocol. The medium was aspirated and the cells washed once with PBS. Alamar blue 
(dilution 1/250 from a stock solution of 1mg/ml) in complete medium was added in 
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each well and the plates were incubated for 4 hrs at 37°C. Fluorescence was read 
immediately after incubation on a BMG plate reader (LabTech, Germany) and it was 
quantified using excitation and emission wavelengths of 530-560nm and 590nm, 
respectively. Blank control wells containing medium and Alamar Blue dye only without 
cells were included as negative control. Relative fluorescence was calculated by 
subtracting the average of the negative controls from each of the well readings. Each 
experiment was carried out in four replicate wells for all conditions tested, and all the 
experiments were done in triplicate. 
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3 GENOMIC ANALYSIS  
 
3.1 DNA extraction and qualification 
DNA was obtained by QIAmp AllPrep DNA/RNA mini kit (Qiagen). Two elutions in 
nuclease-free water were performed to obtain a final volume of 100 µl for each sample. 
Next-generation sequencing (NGS) suitability of extracted DNA was evaluated and was 
quantified using NanoDrop-ND2000 and Qubit fluorometer (Thermo Fisher) as reported 
in a previous study (Simbolo et al., 2013). Furthermore, a multiplex PCR was developed 
according to previous study (Zamò et al., 2012) to verify DNA integrity and multiplex 
suitability. 
 
3.2 Mutational analysis by next-generation targeted sequencing 
Five multigene panels were used to investigate mutational status of 76 genes. The 
custom panels target genes selected according to recent studies (Bailey et al., 2016; 
Biankin et al., 2012; Waddell et al., 2015) and reported in Table 4. Twenty nanograms 
of DNA were used for each multiplex PCR amplification. The quality of the obtained 
libraries was evaluated by the Agilent 2100 Bioanalyzer on-chip electrophoresis 
(Agilent Technologies). Emulsion PCR to construct the libraries of clonal sequences 
was performed with the Ion OneTouch™ OT2 System (Thermo Fisher). Sequencing 
was run on the Ion Proton (PI, Thermo Fisher) loaded with Ion PI Chip v2. Data 
analysis, including alignment to the hg19 human reference genome and variant calling, 
was done using the Torrent Suite Software v.5.0 (Thermo Fisher). Filtered variants were 
annotated using a custom pipeline based on vcflib (https://github.com/ekg/vcflib), 
SnpSift (Cingolani et al., 2012), the Variant Effect Predictor (VEP) software (McLaren 
et al., 2010) and NCBI RefSeq database. Additionally, alignments were visually verified 
with the Integrative Genomics Viewer (IGV) v2.3 (Robinson et al., 2011) to further 
confirm the presence of mutations identified by targeted sequencing. 
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Table 4. PDAC custom panels. 
Custom 1 Custom 2 Custom 3 Custom 4 Custom 5 
APC BRCA1 ARID2 RBM10 ACVR1A 
ATM BRCA2 SMARCA1 SF3B1 ACVR1B 
BRAF ATM SMARCA2 U2AF1 ACVR2 
CDH1 PALB2 SMARCA3 U2AF2 TGFBR1 
CDKN2A RPA1 SMARCA4 RBM6 TGFBR2 
CTNNB1 REV3L PBRM1 SF3A1 ACVR1C 
EGFR STK11 DPF1 PRPF40A ACVR2B 
ERBB2   DPF2 SF1 SMAD4 
ERBB4   DPF3 PRPF40B SMAD1 
FBXW7   ARID1B RNF43 SMAD2 
FGFR3   KMT2C ROBO1 SMAD3 
FLT3   KDM6A ROBO2 SMAD5 
GNAS   KDM5C SLIT2 SMAD9 
HRAS   MEF2C SRGAP1   
KDR   KMT2D SRGAP2   
KRAS   SETD2 SRGAP3   
NRAS   BAP1 ARHGAP4   
PIK3CA     ROBO3   
SMAD4     ROBO4   
TP53         
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3.3 Copy number variation calling 
CNV analysis was performed on IonReporter 5.0 software (ThermoFisher) with the 
CNV single sample workflow. A specific baseline was built using normal and well 
characterised DNA without genomic structural aberrations (10 male DNA extracted 
from normal tissues). The baseline was matched to the sequences of the primary PDAC 
tumours samples and corresponding models to obtain CNV status of the genes analysed. 
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4 FLOW CYTOMETRY 
 
 
4.1 Flow cytometry analysis 
For flow cytometry analysis, single primary pancreatic cells were stained using different 
combinations of antibodies (Table 5). To evaluate autofluorescence, adherent cells and 
spheres were incubated with riboflavin overnight or 3hrs for organoid cells as 
previously published (Miranda-Lorenzo et al., 2014). DAPI was used for exclusion of 
dead cells and isotype matched antibodies were used as negative controls. Cells were 
acquired with a LSRII Fortessa Instrument (BD Biosciences) and data were analysed 
with FlowJo 10.0 software (Tree Star). 
 
Table 5.  List of antibodies used for the analysis of primary pancreatic cells using flow cytometry. 
Antibodies (clone) Dilution Manufacturer Cat. number # 
PerCP/Cy5.5 anti-human 
CD326 (Ep-CAM) 
1/20 Cambridge Bioscience 324214 
CD133/1 (AC133)-PE 1/66.7 Miltenyi 130-080-801 
Mouse anti-Human CD44 
(Pgp-1), FITC 
1/10 BD Bioscience 555478 
APC anti-human CD184 
(CXCR4) 
1/10 Cambridge Bioscience 306510 
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5 RNA ANALYSIS 
 
5.1 RNA extraction 
Total RNA from human pancreatic cancer cells was extracted using RNeasy mini kit 
(Qiagen) according to the manufacturer‟s instructions. Extracted RNA was quantified 
using the NanoDrop machine. 
 
5.2 RT-qPCR 
One microgram of total RNA was reverse-transcribed with QuantiTect Reverse 
Transcription Kit (Qiagen). Quantitative real-time PCR was performed with an Applied 
Biosystems 7500 real-time thermocycler (Applied Biosystems) using miScript SYBR® 
Green PCR kit (Qiagen) as per the manufacturer‟s instructions. Primers used are listed 
in Table 6. 
 
Table 6.  RT-qPCR primers. 
Gene Primer sense Primer antisense 
KLF4 acccacacaggtgagaaacc atgtgtaaggcgaggtggtc 
SOX2 agaaccccaagatgcacaac cggggccggtatttataatc 
NANOG cctgtgatttgtgggcctga tgcgacactcttctctgcag 
OCT 3/4 cttgctgcagaagtgggtggaggaa ctgcagtgtgggtttcgggca 
BMI1 ttctttgaccagaacagattgg gcatcacagtcattgctgct 
hHPRT tgacactggcaaaacaatgca ggtccttttcaccagcaagct 
hUBC atttgggtcgcggttcttg tgccttgacattctcgatggt 
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6 IMMUNOHISTOCHEMICAL ANALYSIS 
 
 
Organoids were recovered from matrigel as previously described (paragraph 2.3). 
Organoid pellets were washed with 1X PBS and fixed with 4% paraformaldehyde at 
room temperature under constant agitation for 30 min. Following fixation the organoids 
were centrifuged for 5 minutes at 2000rpm and the supernatant was removed. The 
organoid pellet was washed with 1X PBS and resuspended in approximately 100µl of 
2% of agarose. Once the agarose solidified, the samples were stored in 70% EtOH prior 
to paraffin embedding and sectioning. For histopathological analysis, FFPE blocks were 
serially sectioned (3µm thick) and stained with hematoxylin and eosin (H&E) for 
morphological analysis. For immunofluorescence staining the paraffin slides were 
deparaffinized in Xylene for 10 min and rehydrated first with 100% ethanol for 10 min, 
in 70% ethanol for other 10 minutes and then in distilled water.  Antigen retrieval was 
performed by boiling the slides in citric acid buffer (pH6) or Tris-EDTA buffer (pH9), 
in the 2100 Antigen Retriever for ~20 min and cooling for 60 min at room temperature. 
The slides were then washed 3 times for 5 min each in 1x PBS and tissue sections were 
blocked with 3% goat serum (Sigma) in 1x PBS with 0.5% BSA (Sigma) for 1 hr at 
room temperature (RT). The sections were incubated with the primary antibody in 
PBS/0.5%BSA O/N at 4⁰C (Table 7) and washed with 1X PBS 3 times for 5 minutes. 
The following day the slides were incubated with secondary antibodies in 
PBS/0.5%BSA (all from Fisher Scientific) for 1 hr in the dark at RT. Finally the slides 
were washed in 1x PBS twice for 5 minutes and incubated in PBS supplemented with 
0.5% BSA and DAPI for 30min in the dark at RT. The slides were washed twice with 
PBS for 5 minutes and mounted with mounting medium and, were analysed using a 
Fluorescent confocal microscope. 
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Table 7.  List of antibodies used for the analysis of primary pancreatic cells using immunofluorescence. 
Primary antibody Manufacturer 
Antigen 
retrievel 
buffer 
Primary antibody 
incubation 
conditions 
Secondary antibody 
Rabbit polyclonal to 
EpCAM ab71916 
Abcam Tris-EDTA 1:1000 O/N 4°C 
1:500 Alexa Fluor 488 
Donkey anti-Rabbit 
IgG (H+L) 
Mouse monoclonal 
[RCK108] to 
Cytokeratin 19  
ab9221 
Abcam Citric Acid 1:100 O/N 4°C 
1:500 Alexa Fluor 555 
Goat anti-Mouse IgG 
(H+L) 
Rabbit monoclonal 
[UMB2] to CXCR4 
ab124824 
Abcam Citric Acid 1:100 O/N 4°C 
1:500 Alexa Fluor 488 
Donkey anti-Rabbit 
IgG (H+L) 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
7 IN VIVO EXPERIMENTS 
 
Pancreatic organoids were dissociated as described in paragraph 2.3, counted and 
resuspended in 50µl of Matrigel
TM
 (Corning) and kept on ice. Organoid cells (20.000 
cells) were injected subcutaneously into the left and right lower flanks of 4-to 6-week 
old female NOD SCID and NU (NCr)-FoxN1nu mice. Growth of transplants was 
monitored weekly by palpation. 
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RESULTS 
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1 Characterization of Primary ductal cell culture 
 
Four different PDXs (1953, 2636, 140114, 215) were used in this study. Viable 
specimens from early passage xenografts of 4 cases were used to generate in vitro 
models, including monolayer cell cultures, spheres and organoids. Expression of stem 
cell markers was assessed by flow cytometry in all cases and mRNA expression of 
pluripotent genes was assessed in three cases. Two cases (1953, and 140114) were 
transplanted in immunodeficient mice and drug sensitivity was tested in an index case 
(1953). Immunohistochemical analysis was performed on two cases (1953, and 
140114).  
 
 
1.1  Analysis of pancreatic cancer stem cell markers 
 
It has been described by Herman et al. (2007) that primary pancreatic CSCs can be 
enriched in vitro by culturing pancreatic cancer cells as anchorage-independent three-
dimensional colonies, also termed spheres. Spheres are mainly composed of 
differentiated cells, while a small number of cells possess stem cell-like properties 
including the ability to form secondary spheres. In the present study, we studied 
pancreatic CSCs in cells isolated from 4 different human pancreatic adenocarcinoma 
xenografts. Cells were isolated from early passage xenografts, and cultured as low 
passage adherent cells or spheres. Human pancreatic cancer cells were phenotyped by 
flow cytometry for the expression of CSCs markers, and as previously reported 
(Lonardo et al., 2011), spheres resulted enriched for CD133
+
 cells. In contrast, cells 
expressing CD44 were not consistently enriched in sphere cultures, mostly likely 
reflecting anchorage-independent culture conditions (Figure 9 and Supplementary 
Fig.1). 
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Figure 9. Representative flow cytometry analysis for the indicated markers in primary PDAC cells 
cultured and sphere cultures. Plots shown are representative of the case 1953. 
 
 
 
Recently, it has been demonstrated in freshly digested tumours from PDAC PDXs as 
well as in primary patient tumours the presence of a distinct autofluorescent population 
which was shown to be a marker of CSCs (Miranda-Lorenzo et al., 2014). Therefore, 
we examined the existence of this subpopulation in our PDAC PDX tumours. We 
observed cells with this phenotype in PDX-derived adherent cultures, a population 
which resulted consistently enriched for in spheres (Figure 10 and supplementary Fig. 
2). 
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Figure 10. Flow cytometry analysis of autofluorescent content in adherent (left) and sphere cultures 
(right). Autofluorescent cells are excited with a 488-nm blue laser and best selected as the intersection 
with filters 530/40 and 580/30. 
 
 
1.2. Self-renewal capacity of pancreatic CSCs 
 
Sphere-forming assays have been widely used to retrospectively identify stem cells 
based on their capacity to self-renew and differentiate at the single cell level in vitro. 
Culture of primary pancreatic cells in suspension as spheres allows cells to remain 
undifferentiated, thus generating spheres which are rich in stem-cells (1
st
 generation 
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spheres). Due to their higher content in stem cells these spheres, following enzymatic 
dissociation, have the ability to give rise to secondary spheres at a higher rate 
demonstrating functionally their increased stemness (Figure 11  and Supplementary 
Fig. 3). 
 
 
 
 
Figure 11. Representative sphere numbers and diameters (µm) for primary cell culture over one 
generation (gen.). Data are representative of 1953 primary PDAC PDX-derived in vitro cultures (n=3, 
each performed in triplicate). Error bars, s.d.  
 
 
1.3  Pancreatic CSCs express Pluripotency-associated genes 
 
It has been recently shown that like stem cells, CSCs up-regulate the expression of 
pluripotency-associated genes (Liu et al., 2013). QPCR analysis for the expression of 
pluripotency-associated genes revealed that spheres over-expressed NANOG, KLF4, 
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SOX2, BMI1, and OCT3/4 as compared to the adherent cell population (Figure 12) , as 
described previously (Lonardo et al., 2011; Miranda-Lorenzo et al., 2014). 
 
 
 
 
Figure 12. QPCR analysis of pluripotency-associated genes in spheres compared to adherent cultures of 
different PDX-tumours.  
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2 Human PDAC Organoids  
 
 
2.1 PDAC organoids express typical markers of primary disease 
 
 
 
Recently, continuously proliferating, normal and tumour pancreatic organoids were 
derived from adult murine ductal cells (Huch et al., 2013). We optimized this approach 
to generate organoid cultures from primary PDX-tumours. We isolated primary cell 
cultures from 3 different PDAC PDX-tumours to establish organoids in 3D culture. 3D 
in vitro culture system for the long-term expansion of human PDAC cells was generated 
combining Matrigel, wich acts as extracellular-matrix (ECM), with medium containing 
growth factors as EGF, FGFs, and Rspo1. Under these culture conditions, pancreatic 
cells can be expanded for months in culture. A combination of factors and nutrients 
critical for pancreas development induced polarized 3D structures from single cells of 
primary PDAC cultures. Following 15 days in 3D culture conditions, epithelial cells 
proliferate and organize into 3D organoid structures, which are characterized by the 
presence of a centrally-localized, hollow lumen (Figure 13). 
 
 
Figure 13. Left, H&E-staining of one organoid. Phase contrast microscopy photo depicting the 
morphology of day 15 organoids, middle (right; higher magnification image of one organoid). Data are 
representative of the case 1953. 
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To determine the contribution of different pancreatic lineages to the organoids, we 
evaluated the expression of pancreatic lineage markers in these cultures. Cells within 
organoids were demonstrated to express epithelium-associated cytokeratin 19. 
Furthermore, pancreatic organoids were shown to be positive for EpCAM, confirming 
their epithelial lineage identity (Figure 14). 
 
 
 
 
Figure 14. Immunofluorescent staining of 15 day-old organoids for the epithelial marker EpCAM and 
cytokeratin 19 (KRT19).  Data are representative of a case 1953. 
 
 
 
2.2 Mutational profile analysis identified no molecular changes in genetic 
landscape between primary tumour tissues and their three- dimensional models 
 
In order to confirm the genetic stability of the 3D CSC-enriched models we performed 
mutational profile analysis for a list of genes commonly associated with PDAC (Bailey 
et al., 2016; Biankin et al., 2012; Waddell et al., 2015). Multigene sequencing achieved 
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mean read length of 118 base pairs and a mean coverage of 2132x, with 95.8% target 
bases covered more than 50x. A minimum coverage of 20x was obtained in all cases. 
Mutations identified in 76 genes analyzed are summarized in Table 8 and illustrated in 
Figure 15. 
 
 
Primary tumour sample 1608 1953 2636 
Neoplastic Cellularity 50% 50% 67% 
ARID1A 
  
Asp1219GlyfsTer9 
BRCA2 Lys3326Ter Val2728Ile 
 KRAS Gly12Val Gly12Asp Gly12Asp 
SMAD4 Ile429CysfsTer7 
  TP53 Thr81AsnfsTer42 
   
Table 8. Detail of somatic mutations identified in primary tumour samples. 
 
 
All mutations detected in primary tissue and xenograft-tumours were observed in both 
3D models (organoids and spheres). In detail: KRAS mutation was identified in all 
samples analysed; two samples showed mutation in BRCA2 (a nonsense and a missense 
mutation), while frameshift mutations were observed each in one sample in TP53, 
SMAD4 and ARID1A genes. Of note, sample 1608 and its models showed 
simultaneously mutations affecting KRAS, TP53, SMAD4 and BRCA2. No additional 
mutations that were present in the original tumours were observed in corresponding 
models.    
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Figure 15. Genetic profile comparison between sphere, organoid cultures and their primary tumours. The 
cases 1608, 1953 and 2636 are arranged from left to right. Type of sample, mutation (A) and CNV (B) of 
altered genes are represented according to color legend below. 
 
 
2.3 Copy number variation analysis in primary tumour tissues and their three- 
dimensional models 
 
Copy number variation (CNV) analysis was performed on three primary PDAC tumours 
and their matched models (xenografts, spheres and organoids). Homozygous deletion 
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and loss of the heterozygosity (LOH) affected known tumour soppressor genes 
CDKN2A, SMAD4 and TP53 as depicted in Figure 15B.  CNV profile of the three-
dimensional models revealed no change compared to xenograft tumours, which they 
derived from, except for homozygous deletion of CDK2A observed exclusively in the 
spheres but not in organoid cultures from PDX 2636. More differences at CNV level 
were observed when comparing primary tumours and corresponding models for the 
cases 1953 and 2636 (Figure 15), which might be due to the different neoplastic cell 
contents of the specimens analysed rather than to the genetic drift upon model 
establishment. 
 
 
2.4 Transplantation of PDAC organoids morphologically resemble PDX 
 
To test whether the organoid cultures could generate tumours in vivo, we 
subcutaneously injected 20,000 cells from two independent organoid cultures (1953, 
140114) into Nude mice (3 mice per organoid culture). All injections resulted in tumour 
growth within 4–7 weeks. The organoid-derived tumours maintained the 
histoarchitectures present in the PDX- and primary tumour from which they were 
derived (Figure 16), as well as similar expression of differentiation markers, including 
CK19 (Figure 17). Thus, organoid-derived tumours conserve histological organization, 
differentiation status and morphologic heterogeneity observed in primary PDACs. 
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Figure 16. Organization of H&E-stained human primary PDAC (left), PDX-tumour (middle) and 
Organoid-tumour (right panel). Data are representative of one case (1953). 
 
 
 
 
62 
 
 
 
Figure 17. Immunofluorescence staining of epithelial markers EpCAM and cytokeratin 19 (KRT19) in 
PDX- and organoid-derived tumour. Data are representative of one case (1953).  
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3 Characterization of PDAC-Organoid cultures 
 
3.1 PDAC organoids are enriched for cells showing stemness  
Following establishment and characterization of PDAC cell cultures, we asked whether 
organoids were enriched for CSCs compared to corresponding adherent cell cultures, 
and spheroids. Flow cytometric analysis revealed no major changes in the percentage of 
epithelial cells, as marked by Epithelial Cell Adhesion Molecule (EPCAM). While 
monolayer cell cultures from PDX-tumours contained less than 4% of CD133+ cells, 
approximately 30% of the organoid cells expressed CD133 (Figure 18). In agreement 
with this finding, organoid-derived cells exhibited higher expression of stem cell 
markers CD44 and CXCR4 (Figure 18) as well as increased level of autofluorescence 
compared to adherent and sphere-derived cells (Figure 19 and supplementary Fig. 4). 
 
 
Figure 18. Flow cytometry analysis for markers EpCAM, CD133, CD44, CXCR4 in adherent, sphere and 
organoid cultures. 
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Figure 19. Flow cytometry analysis of autofluorescent content in PDAC organoid cells. Autofluorescent 
cells are excited with a 488-nm blue laser and best selected as the intersection with filters 530/40 and 
580/30. 
 
 
 
In order to further assess stemness of organoids, an assay similar to the sphere 
formation described previously was performed. In detail, starting from adherent 
cultures, which are considered to have the lowest representation of stem cells, 3 wells of 
a 24-well plate were seeded with 10.000 cells per well and the number of formed 
organoids by day 10 was counted for each well (1
st 
generation organoids). Following 
sequential culturing in organoid conditions, cells showed an increased number of 
secondary organoids compared to the first generation (Figure 20 and Supplementary 
Fig. 5), in a similar fashion as observed in sphere cultures (Figure 11), highlighting the 
enhanced stemness potential of PDAC organoids. Collectively, these data showed that 
PDAC organoids contain CSCs in a similar level to spheres and are therefore a suitable 
culture system to model CSCs in vitro. 
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Figure 20. Representative organoid numbers over one generation (gen.). Data are representative of 1953 
primary PDAC PDX-derived in vitro culture (n=2, each performed in triplicate). Error bars, s.d.  
 
 
 
3.2  Cancer Stem cell related genes 
 
Using qRT PCR, we determined the relative expression levels of a range of trascription 
factors NANOG, BMI1, KLF4, SOX2 and OCT3/4 wich have been recently 
demonstrated as characteristic of pluripotent stem cells. Data showed an increased 
expression of these markers in organoid cultures when compared to adherent cultures 
(Figure 21 and supplementary Fig. 6). Commonly used markers of the stem cell 
compartment, such as KLF4, OCT3/4 and BMI1, were upregulated compared to sphere 
cultures. 
66 
 
 
 
Figure 21. QPCR analysis of pluripotency-associated genes in organoid and sphere cultures compared to 
adherent cells of a representative  PDX-Tumour, case 1953. 
 
 
 
3.3 PDAC organoids express stem cell markers 
 
Using immunofluorescent staining for stem cell markers, we analyzed PDAC organoids 
for the presence of pancreatic CSCs. We conducted immunohistochemical analyses of 
various CSC markers, in order to confirm their expression. Paraffin-embedded 
organoids showed expression of CXCR4 with membrane localization (Figure 22). Data 
confirm the 1-2% of marker expression observed by flow cytometry (Figure 18).  
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Figure 22. Confocal images of 15 days organoids immunostained for stem cell marker CXCR4 (green) 
and DAPI (blue). Data are representative of the case 1953.  
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4 PDAC organoids showed resistance to therapy  
 
Since CSC are believed to be the mediating cell type behind chemoresistance, and since 
our data show that organoid cells display a more CSC phenotype, we sought to exploit 
this cell population for the purposes of therapeutic applications. Specifically, we 
analyzed organoid cultures derived from an index PDX case (1953). We treated 
adherent cells and organoid cultures with Gemcitabine and Abraxane alone or in 
combination for 7 day at the end of which we assessed cell viability. Organoids were 
largely insensitive to these chemotherapeutic drugs, whereas adherent cultures resulted 
in a viability decrease when treated with a combination of drugs (Figure 23). 
 
 
 
 
 
 
 
 
Figure 23. Representative cell viability comparison between adherent cells (left) and organoid cultures 
(right) from one PDX-Tumuor (1953) following treatment with Gemcitabine and Abraxane. Error bars, 
s.d. 
 
 
Unlike 2D cell cultures, 3D systems have recently emerged as advanced drug screening 
platforms since they more adequately mimic in vivo conditions. As depicted in Figure 
24, spheres and organoid cultures were incubated with chemotherapeutic drugs for 
seven days and cell viability was evaluated counting the number of formed structures 
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per mL. Our preliminary analysis showed that pancreatic organoids exhibit a similar 
response to therapeutic drugs as spheres, reflecting their inherent stemness properties. 
 
 
 
 
 
Figure 24. Representative sphere (top) and organoid (bottom) forming capacity of one primary PDAC 
cell culture (1953) following treatment with Gemcitabine and Abraxane for 7 days. 
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DISCUSSION 
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In light of the still devastating prognosis for PDAC patients, the identification of 
pancreatic CSCs with exclusive tumorigenicity in 2007 (Hermann et al., 2007) created 
an entirely new research field spurring renewed hope for the development of novel stem 
cell-specific targeted therapies. It has been recently demonstrated that 3D models, 
compared to 2D models, mimic tumour microenvironments better, facilitate the 
formation of ECM, show a more realistic drug response, exhibit more adequate 
proliferation rates with more representative cellular morphology. We report conditions 
for inducing the pancreatic cancer cells to grow as organoids in order to probe their 
potential values as tool to study CSCs. Previous reports have used mouse and human 
pancreas tissue to develop organoid cultures of ductal cells, which can be manipulated 
and transplanted in vivo (Boj et al., 2015; Huch et al., 2013). We modified this approach 
to develop a 3D culture system that allows the long-term expansion of pancreatic cells 
from PDX-tumours. Among the typical marker associated with pancreas development, 
we found that all the cells composed organoids express Cytokeratin 19, confirming their 
epithelial origin.  The stemness potential of cells in organoids was assessed by: (i) 
expression of stem cell surface markers; (ii) expression of pluripotency-associated 
genes; (iii) self-renewing ability of neoplastic cells. For the first time, our results clearly 
demonstrate an enhanced stemness potential of the organoid system compared to other 
models of PDAC, which include monolayer cell cultures, 3D spheres, and PDXs. In 
particular, the percentage of neoplastic cells expressing stem cell markers was found to 
be strikingly higher in organoids than in corresponding PDXs, which makes the former 
a better platform to study CSCs. 
Unlike more traditional in vitro systems, organoids are similar to primary tissue in both 
their composition and architecture. A recent study reported a method to establish 
tumour organoids that have histological features consistent with parental 
adenocarcinoma (Boj et al., 2015). This holds true for our system as we showed that 
transplantation of organoid cells into immunodeficient mice generated tumours that 
morphologically resembled primary tissues from which cultures were derived. In 
addition, we revealed that pancreatic organoids shared similar genetic abnormalities 
with their corresponding primary tumours. Our data support the use of this technology 
to model the disease and find new therapeutic targets for PDAC. PDAC is extremely 
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chemorefractory, with available drugs only giving modest benefit to patients. In a recent 
study published in 2013 by Von Hoff, it has been shown that combining gemcitabine 
with abraxane leads to an improvement in survival (Von Hoff et al., 2013). In particular, 
the survival curves showed a median improvement of 1.8 months and an improvement 
of 3.4 months at the time point when 25% of the patients were alive. However, even 
when an initial response to the treatment is observed, tumours often progress. CSCs are 
believed to be the cause of the observed tumour resistance to the treatment as they can 
rapidly repopulate tumour mass. Therefore, targeting CSCs might improve cancer 
treatments. Nevertheless, to achieve these improvements, a key step is to identify and 
characterize the targets of such treatments – CSCs – in the respective tumour types. 
Preclinical testing of candidate drugs in PDAC almost invariably relies on the use of 
monolayer cell cultures, which are difficult to establish from resected tumours and have 
been shown to poorly predict responses to treatment. PDXs are considered a better 
system to predict therapeutic responses in PDAC, while their generation being costly 
and time consuming. Using an index case, we demonstrated here that PDAC organoids 
are highly resistant, thereby reflecting inherent stem properties, and exhibit a 
resistance/sensitivity profile similar to that of corresponding PDX. Our data suggest that 
human PDAC-organoids represent an important resource for developing personalized 
treatment.  
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CONCLUSIONS 
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We have accumulated compelling evidence establishing PDAC organoids as novel tool 
for study pancreatic cancer stem cells. Therefore, we conclude: 
 
1. PDAC organoids express typical markers of primary disease. 
2. Organoid cells are enriched in stemness-associated genes as compared to 
adherent cell cultures. 
3. Organoids  cells showed self-renewal properties in vitro as showed the organoid 
formation capacity assay. 
4. Organoid cells are tumorigenic, as we showed with our in vivo experiments. 
5. Transplantation of PDAC organoids morphologically resembles PDX. 
6. Organoids mantain the same genetic profile of the parental tumour. 
7. Organoid cultures are more resistant to standard chemotherapy Gemcitabine and 
Abraxane.  
 
  
 
Related to this, the defined nature of the culture conditions means that organoid cultures 
are ideal for studying stem cells in a 3D environment, which remains a relatively 
unexplored area for pancreatic cancer. In addition to their role in investigating stem cell 
biology, 3D organoid cultures promise to be of considerable biomedical utility.  
 
 
 
 
 
 
75 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
American Cancer Society Cancer Facts & Figures 2016. 
Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.-M., Gingras, M.-C., Miller, 
D.K., Christ, A.N., Bruxner, T.J.C., Quinn, M.C., et al. (2016). Genomic analyses 
identify molecular subtypes of pancreatic cancer. Nature 531, 47–52. 
Bardeesy, N., and DePinho, R.A. (2002). Pancreatic cancer biology and genetics. Nat. 
Rev. Cancer 2, 897–909. 
Beck, B., and Blanpain, C. (2013). Unravelling cancer stem cell potential. Nat. Rev. 
Cancer 13, 727–738. 
Bhushan, A., Itoh, N., Kato, S., Thiery, J.P., Czernichow, P., Bellusci, S., and 
Scharfmann, R. (2001). Fgf10 is essential for maintaining the proliferative capacity of 
epithelial progenitor cells during early pancreatic organogenesis. Development 128, 
5109–5117. 
Biankin, A.V., Waddell, N., Kassahn, K.S., Gingras, M.-C., Muthuswamy, L.B., Johns, 
A.L., Miller, D.K., Wilson, P.J., Patch, A.-M., Wu, J., et al. (2012). Pancreatic cancer 
genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405. 
Boj, S.F., Hwang, C.-I., Baker, L.A., Chio, I.I.C., Engle, D.D., Corbo, V., Jager, M., 
Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. (2015). Organoid models of human 
and mouse ductal pancreatic cancer. Cell 160, 324–338. 
Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737. 
Bosman, F.T. (2010). WHO classification of tumours of the digestive system (Lyon: 
International Agency for Research on Cancer). 
Brooks, M.D., Burness, M.L., and Wicha, M.S. (2015). Therapeutic Implications of 
Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell 17, 260–271. 
Burris, H.A. (2005). Recent updates on the role of chemotherapy in pancreatic cancer. 
Semin. Oncol. 32, S1-3. 
77 
 
Chaffer, C.L., Brueckmann, I., Scheel, C., Kaestli, A.J., Wiggins, P.A., Rodrigues, L.O., 
Brooks, M., Reinhardt, F., Su, Y., Polyak, K., et al. (2011). Normal and neoplastic 
nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. 
U.S.A. 108, 7950–7955. 
Chaffer, C.L., Marjanovic, N.D., Lee, T., Bell, G., Kleer, C.G., Reinhardt, F., 
D‟Alessio, A.C., Young, R.A., and Weinberg, R.A. (2013). Poised chromatin at the 
ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 
154, 61–74. 
Charles, N., Ozawa, T., Squatrito, M., Bleau, A.-M., Brennan, C.W., Hambardzumyan, 
D., and Holland, E.C. (2010). Perivascular nitric oxide activates notch signaling and 
promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6, 141–
152. 
Chen, J., Li, Y., Yu, T.-S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada, L.F. 
(2012). A restricted cell population propagates glioblastoma growth after chemotherapy. 
Nature 488, 522–526. 
Chen, K., Li, Z., Jiang, P., Zhang, X., Zhang, Y., Jiang, Y., He, Y., and Li, X. (2014). 
Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis 
and poor prognosis in pancreatic carcinoma. Oncol. Rep. 32, 755–763. 
Cingolani, P., Patel, V.M., Coon, M., Nguyen, T., Land, S.J., Ruden, D.M., and Lu, X. 
(2012). Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational 
Studies with a New Program, SnpSift. Front Genet 3, 35. 
Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H.M., Jones, D.L., 
Visvader, J., Weissman, I.L., and Wahl, G.M. (2006). Cancer stem cells--perspectives 
on current status and future directions: AACR Workshop on cancer stem cells. Cancer 
Res. 66, 9339–9344. 
Clevers, H. (2016). Modeling Development and Disease with Organoids. Cell 165, 
1586–1597. 
78 
 
Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. (2005). Prospective 
identification of tumorigenic prostate cancer stem cells. Cancer Res.  65,10946–10951. 
Cojoc, M., Mäbert, K., Muders, M.H., and Dubrovska, A. (2015). A role for cancer 
stem cells in therapy resistance: cellular and molecular mechanisms. Semin. Cancer 
Biol. 31, 16–27. 
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., 
Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011). 
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 
364, 1817–1825. 
Deng, S., Yang, X., Lassus, H., Liang, S., Kaur, S., Ye, Q., Li, C., Wang, L.-P., Roby, 
K.F., Orsulic, S., et al. (2010). Distinct expression levels and patterns of stem cell 
marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. 
PLoS ONE 5, e10277. 
Dorado, J., Lonardo, E., Miranda-Lorenzo, I., and Heeschen, C. (2011). Pancreatic 
cancer stem cells: new insights and perspectives. J. Gastroenterol. 46, 966–973. 
Driessens, G., Beck, B., Caauwe, A., Simons, B.D., and Blanpain, C. (2012). Defining 
the mode of tumour growth by clonal analysis. Nature 488, 527–530. 
Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco 
L., Peschle C., De Maria R. (2008). Identification and expansion of the tumorigenic 
lung cancer stem cell population. Cell Death Differ. 15, 504–514. 
Fatehullah, A., Tan, S.H., and Barker, N. (2016). Organoids as an in vitro model of 
human development and disease. Nat. Cell Biol. 18, 246–254. 
Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, 
C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., et al. (2007). Blockade of 
hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm 
for combination therapy in solid cancers. Cancer Res. 67, 2187–2196. 
Greaves, M., and Maley, C.C. (2012). Clonal evolution in cancer. Nature 481, 306–313. 
79 
 
Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., and 
Lander, E.S. (2009). Identification of selective inhibitors of cancer stem cells by high-
throughput screening. Cell 138, 645–659. 
Han, H., and Von Hoff, D.D. (2013). SnapShot: pancreatic cancer. Cancer Cell 23, 424–
424.e1. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57–70. 
Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M., Bruns, 
C.J., and Heeschen, C. (2007). Distinct populations of cancer stem cells determine 
tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 
313–323. 
Hermann, P.C., Bhaskar, S., Cioffi, M., and Heeschen, C. (2010). Cancer stem cells in 
solid tumors. Semin. Cancer Biol. 20, 77–84. 
Herreros-Villanueva, M., Zhang, J.-S., Koenig, A., Abel, E.V., Smyrk, T.C., Bamlet, 
W.R., de Narvajas, A. a.-M., Gomez, T.S., Simeone, D.M., Bujanda, L., et al. (2013). 
SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic 
cancer cells. Oncogenesis 2, e61. 
Herreros-Villanueva, M., Bujanda, L., Billadeau, D.D., and Zhang, J.-S. (2014). 
Embryonic stem cell factors and pancreatic cancer. World J. Gastroenterol. 20, 2247–
2254. 
Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A. (2006). 
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218–1249. 
Hidalgo, M. (2010). Pancreatic cancer. N. Engl. J. Med. 362, 1605–1617. 
Hou, Y.-C., Chao, Y.-J., Tung, H.-L., Wang, H.-C., and Shan, Y.-S. (2014). 
Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive 
tumor-associated macrophages is a predictor of survival in pancreatic ductal 
adenocarcinoma. Cancer 120, 2766–2777. 
80 
 
Huang, L., Holtzinger, A., Jagan, I., BeGora, M., Lohse, I., Ngai, N., Nostro, C., Wang, 
R., Muthuswamy, L.B., Crawford, H.C., et al. (2015). Ductal pancreatic cancer 
modeling and drug screening using human pluripotent stem cell- and patient-derived 
tumor organoids. Nat. Med. 21, 1364–1371. 
Huch, M., Dorrell, C., Boj, S.F., van Es, J.H., Li, V.S.W., van de Wetering, M., Sato, 
T., Hamer, K., Sasaki, N., Finegold, M.J., et al. (2013). In vitro expansion of single 
Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 494, 247–250. 
Hustinx, S.R., Leoni, L.M., Yeo, C.J., Brown, P.N., Goggins, M., Kern, S.E., Hruban, 
R.H., and Maitra, A. (2005). Concordant loss of MTAP and p16/CDKN2A expression 
in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a 
noninvasive precursor lesion. Mod. Pathol. 18, 959–963. 
Iliopoulos, D., Hirsch, H.A., Wang, G., and Struhl, K. (2011). Inducible formation of 
breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via 
IL6 secretion. Proc. Natl. Acad. Sci. U.S.A. 108, 1397–1402. 
Immervoll, H., Hoem, D., Sakariassen, P.Ø., Steffensen, O.J., and Molven, A. (2008). 
Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal 
adenocarcinomas. BMC Cancer 8, 48. 
Immervoll, H., Hoem, D., Steffensen, O.J., Miletic, H., and Molven, A. (2011). 
Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal 
adenocarcinomas: non-overlapping membrane expression in cell populations positive 
for both markers. J. Histochem. Cytochem. 59, 441–455. 
Jimeno, A., Feldmann, G., Suárez-Gauthier, A., Rasheed, Z., Solomon, A., Zou, G.-M., 
Rubio-Viqueira, B., García-García, E., López-Ríos, F., Matsui, W., et al. (2009). A 
direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic 
development. Mol. Cancer Ther. 8, 310–314. 
Kabashima, A., Higuchi, H., Takaishi, H., Matsuzaki, Y., Suzuki, S., Izumiya, M., 
Iizuka, H., Sakai, G., Hozawa, S., Azuma, T., et al. (2009). Side population of 
81 
 
pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal 
transition and invasion. Int. J. Cancer 124, 2771–2779. 
Kim, H.-S., Yoo, S.-Y., Kim, K.-T., Park, J.-T., Kim, H.-J., and Kim, J.-C. (2012). 
Expression of the stem cell markers CD133 and nestin in pancreatic ductal 
adenocarcinoma and clinical relevance. Int J Clin Exp Pathol 5, 754–761. 
Kim, K.-U., Wilson, S.M., Abayasiriwardana, K.S., Collins, R., Fjellbirkeland, L., Xu, 
Z., Jablons, D.M., Nishimura, S.L., and Broaddus, V.C. (2005). A novel in vitro model 
of human mesothelioma for studying tumor biology and apoptotic resistance. Am. J. 
Respir. Cell Mol. Biol. 33, 541–548. 
Klein, W.M., Hruban, R.H., Klein-Szanto, A.J.P., and Wilentz, R.E. (2002). Direct 
correlation between proliferative activity and dysplasia in pancreatic intraepithelial 
neoplasia (PanIN): additional evidence for a recently proposed model of progression. 
Mod. Pathol. 15, 441–447. 
Kleppe, M., and Levine, R.L. (2014). Tumor heterogeneity confounds and illuminates: 
assessing the implications. Nat. Med. 20, 342–344. 
Kreso, A., and Dick, J.E. (2014). Evolution of the cancer stem cell model. Cell Stem 
Cell 14, 275–291. 
Krieg, A., Riemer, J.C., Telan, L.A., Gabbert, H.E., and Knoefel, W.T. (2015). CXCR4-
-A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal 
Adenocarcinoma: A Meta-Analysis. PLoS ONE 10, e0130192. 
Kure, S., Matsuda, Y., Hagio, M., Ueda, J., Naito, Z., and Ishiwata, T. (2012). 
Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and 
pancreatic ductal adenocarcinomas. Int. J. Oncol. 41, 1314–1324. 
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., 
Minden, M., Paterson, B., Caligiuri, M.A., and Dick, J.E. (1994). A cell initiating 
human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–
648. 
82 
 
Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., Wicha, M., Clarke, 
M.F., and Simeone, D.M. (2007). Identification of pancreatic cancer stem cells. Cancer 
Res. 67, 1030–1037. 
Li, X., Zhao, H., Gu, J., and Zheng, L. (2015). Prognostic value of cancer stem cell 
marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic 
review and meta-analysis. Int J Clin Exp Pathol 8, 12084–12092. 
Lin, L., Liu, A., Peng, Z., Lin, H.-J., Li, P.-K., Li, C., and Lin, J. (2011). STAT3 is 
necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71, 
7226–7237. 
Liu, A., Yu, X., and Liu, S. (2013). Pluripotency transcription factors and cancer stem 
cells: small genes make a big difference. Chin J Cancer 32, 483–487. 
Lonardo, E., Hermann, P.C., Mueller, M.-T., Huber, S., Balic, A., Miranda-Lorenzo, I., 
Zagorac, S., Alcala, S., Rodriguez-Arabaolaza, I., Ramirez, J.C., et al. (2011). 
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer 
stem cells and provides a target for combined drug therapy. Cell Stem Cell 9, 433–446. 
Lonardo, E., Cioffi, M., Sancho, P., Crusz, S., and Heeschen, C. (2015). Studying 
Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. 
J Vis Exp e52801. 
McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., and Cunningham, F. (2010). 
Deriving the consequences of genomic variants with the Ensembl API and SNP Effect 
Predictor. Bioinformatics 26, 2069–2070. 
Miranda-Lorenzo, I., Dorado, J., Lonardo, E., Alcala, S., Serrano, A.G., Clausell-
Tormos, J., Cioffi, M., Megias, D., Zagorac, S., Balic, A., et al. (2014). Intracellular 
autofluorescence: a biomarker for epithelial cancer stem cells. Nat. Methods 11, 1161–
1169. 
Morris, J.P., Wang, S.C., and Hebrok, M. (2010). KRAS, Hedgehog, Wnt and the 
twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 
10, 683–695. 
83 
 
O‟Connor, M.L., Xiang, D., Shigdar, S., Macdonald, J., Li, Y., Wang, T., Pu, C., Wang, 
Z., Qiao, L., and Duan, W. (2014). Cancer stem cells: A contentious hypothesis now 
moving forward. Cancer Lett. 344, 180–187. 
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., 
Fahlke, J., Zuelke, C., Burkart, C., et al. (2007). Adjuvant chemotherapy with 
gemcitabine vs observation in patients undergoing curative-intent resection of 
pancreatic cancer: a randomized controlled trial. JAMA 297, 267–277. 
Ogawa, M., Ogawa, S., Bear, C.E., Ahmadi, S., Chin, S., Li, B., Grompe, M., Keller, 
G., Kamath, B.M., and Ghanekar, A. (2015). Directed differentiation of cholangiocytes 
from human pluripotent stem cells. Nat. Biotechnol. 33, 853–861. 
Pardal, R., Clarke, M.F., and Morrison, S.J. (2003). Applying the principles of stem-cell 
biology to cancer. Nat. Rev. Cancer 3, 895–902. 
Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., 
Pierotti M.A., Daidone M.G. (2005). Isolation and in vitro propagation of tumorigenic 
breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506–5511. 
Rasheed, Z.A., Yang, J., Wang, Q., Kowalski, J., Freed, I., Murter, C., Hong, S.-M., 
Koorstra, J.-B., Rajeshkumar, N.V., He, X., et al. (2010). Prognostic significance of 
tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. 
Cancer Inst. 102, 340–351. 
Reynolds B.A., Weiss S. (1992). Generation of neurons and astrocytes from isolated 
cells of the adult mammalian central nervous system. Science. 255, 1707–1710. 
Rheinwald, J.G., and Green, H. (1975). Serial cultivation of strains of human epidermal 
keratinocytes: the formation of keratinizing colonies from single cells. Cell 6, 331–343. 
Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De 
Maria R. (2007).  Identification and expansion of human colon-cancer-initiating cells. 
Nature. 445, 111–115. 
84 
 
Rimann, M., and Graf-Hausner, U. (2012). Synthetic 3D multicellular systems for drug 
development. Curr. Opin. Biotechnol. 23, 803–809. 
Robinson, J.T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., 
and Mesirov, J.P. (2011). Integrative genomics viewer. Nat. Biotechnol. 29, 24–26. 
Rycaj, K., and Tang, D.G. (2015). Cell-of-Origin of Cancer versus Cancer Stem Cells: 
Assays and Interpretations. Cancer Res. 75, 4003–4011. 
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuziodonahue, C., Karikari, 
C., Shi, C., Danenberg, K., Danenberg, P.V., Kuramochi, H., Tanaha, K., Singh, S., 
Salimi-Moosavi, H., Bouraoud, N., Amador, M.L., Altiok, S., Kulesza, P., Yeo, C., 
Messersmith, W., Eshleman, J., Hruban, R.H., Maitra, A. & Hidalgo, M. (2006). An in 
vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res, 
12, 4652-61. 
Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N., Stange, D.E., van 
Es, J.H., Abo, A., Kujala, P., Peters, P.J., et al. (2009). Single Lgr5 stem cells build 
crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265. 
Sato, T., Stange, D.E., Ferrante, M., Vries, R.G.J., Van Es, J.H., Van den Brink, S., Van 
Houdt, W.J., Pronk, A., Van Gorp, J., Siersema, P.D., et al. (2011). Long-term 
expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and 
Barrett‟s epithelium. Gastroenterology 141, 1762–1772. 
Schepers, A.G., Snippert, H.J., Stange, D.E., van den Born, M., van Es, J.H., van de 
Wetering, M., and Clevers, H. (2012). Lineage tracing reveals Lgr5+ stem cell activity 
in mouse intestinal adenomas. Science 337, 730–735. 
Schwitalla, S., Fingerle, A.A., Cammareri, P., Nebelsiek, T., Göktuna, S.I., Ziegler, 
P.K., Canli, O., Heijmans, J., Huels, D.J., Moreaux, G., et al. (2013). Intestinal 
tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. 
Cell 152, 25–38. 
85 
 
Shamir, E.R., and Ewald, A.J. (2014). Three-dimensional organotypic culture: 
experimental models of mammalian biology and disease. Nat. Rev. Mol. Cell Biol. 15, 
647–664. 
Shen, B., Zheng, M.-Q., Lu, J.-W., Jiang, Q., Wang, T.-H., and Huang, X.-E. (2013). 
CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells. Asian 
Pac. J. Cancer Prev. 14, 5403–5408. 
Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J 
Clin 62, 10–29. 
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., and Dirks, 
P.B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 
5821–5828. 
Singh, S.K., Chen, N.-M., Hessmann, E., Siveke, J., Lahmann, M., Singh, G., Voelker, 
N., Vogt, S., Esposito, I., Schmidt, A., et al. (2015). Antithetical NFATc1-Sox2 and 
p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J. 34, 
517–530. 
Simbolo, M., Gottardi, M., Corbo, V., Fassan, M., Mafficini, A., Malpeli, G., Lawlor, 
R.T., and Scarpa, A. (2013). DNA qualification workflow for next generation 
sequencing of histopathological samples. PLoS ONE 8, e62692. 
Thomas, R.M., Kim, J., Revelo-Penafiel, M.P., Angel, R., Dawson, D.W., and Lowy, 
A.M. (2008). The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial 
neoplasia. Gut 57, 1555–1560. 
Uchida N., Buck D.W., He D., Reitsma M.J., Masek M., Phan T.V., Tsukamoto A.S., 
Gage F.H., Weissman I.L. (2009).  Direct isolation of human central nervous system 
stem cells. Proc Natl Acad Sci U S A. 97, 14720–14725. 
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J.H., 
Borovski, T., Tuynman, J.B., Todaro, M., Merz, C., Rodermond, H., et al. (2010). Wnt 
activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. 
Cell Biol. 12, 468–476. 
86 
 
Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., Seay, T., 
Tjulandin, S.A., Ma, W.W., Saleh, M.N., et al. (2013). Increased survival in pancreatic 
cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703. 
Waddell, N., Pajic, M., Patch, A.-M., Chang, D.K., Kassahn, K.S., Bailey, P., Johns, 
A.L., Miller, D., Nones, K., Quek, K., et al. (2015). Whole genomes redefine the 
mutational landscape of pancreatic cancer. Nature 518, 495–501. 
Wang, J.C.Y., and Dick, J.E. (2005). Cancer stem cells: lessons from leukemia. Trends 
Cell Biol. 15, 494–501. 
Weiss, S., Dunne, C., Hewson, J., Wohl, C., Wheatley, M., Peterson, A.C., and 
Reynolds, B.A. (1996). Multipotent CNS stem cells are present in the adult mammalian 
spinal cord and ventricular neuroaxis. J. Neurosci. 16, 7599–7609. 
van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., 
van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015). Prospective 
derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945. 
Virchow R (1855) Editorial. Virchow Arch Pathol Anat Physiol Klin Med 3:23. 
 
Ying, J.-E., Zhu, L.-M., and Liu, B.-X. (2012). Developments in metastatic pancreatic 
cancer: is gemcitabine still the standard? World J. Gastroenterol. 18, 736–745. 
Zamò, A., Bertolaso, A., van Raaij, A.W.M., Mancini, F., Scardoni, M., Montresor, M., 
Menestrina, F., van Krieken, J.H.J.M., Chilosi, M., Groenen, P.J.T.A., et al. (2012). 
Application of microfluidic technology to the BIOMED-2 protocol for detection of B-
cell clonality. J Mol Diagn 14, 30–37. 
Zellmer, V.R., and Zhang, S. (2014). Evolving concepts of tumor heterogeneity. Cell 
Biosci 4, 69. 
Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan P.S., Huang 
T.H., Nephew K.P. (2012). Identification and characterization of ovarian cancer-
initiating cells from primary human tumors. Cancer Res. 68, 4311–4320.  
87 
 
APPENDIX 
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Supplementary Figure 1. Flow cytometry analysis of CD44+CD133+ cells from primary PDAC 2636, 
140114,  and 215 cells cultured as adherent cells or spheres. 
89 
 
 
 
 
 
Supplementary Figure 2. Flow cytometry analysis of autofluorescent content in adherent (left) and 
sphere cultures (right). Autofluorescent cells are excited with a 488-nm blue laser and best selected as the 
intersection with filters 530/40 and 580/30. 
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Supplementary Figure 3. Representative sphere numbers and diameters (µm) for different primary cell 
culture over one generation (gen.). Data are representative of  primary PDAC PDX-derived in vitro 
cultures (n=3, each performed in triplicate). Error bars, s.d.  A, case 140114; B, case 215; C, case 2636. 
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Supplementary Figure 4. Flow cytometry analysis of autofluorescent content in PDAC organoid cells. 
Autofluorescent cells are excited with a 488-nm blue laser and best selected as the intersection with filters 
530/40 and 580/30. 
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Supplementary Figure 5. Representative organoid numbers over one generation (gen.). Data are 
representative of 215, A and 140114, B,  primary PDAC PDX-derived in vitro culture (n=2, each 
performed in triplicate). Error bars, s.d.  
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Supplementary Figure 6.  QPCR analysis of pluripotency-associated genes in organoid and sphere 
cultures compared to adherent cells of a representative  PDX-Tumours (A, case 215; B, case 140114). 
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